

Major Events in the Update Information (UP) Field in Pharmaprojects (Dialog Files 128*,928*, DataStar PHAR*)

- **Additional Launches** — all additional launches, giving details of which markets.
- **Additional Registrations** — additional registrations, with countries given.
- **Change in Indication Status** — all changes in the development status of a compound for a specific disease, where the worldwide status is unchanged.
- **Change in Licensee Status** — all changes in the development status of a compound by a named licensee, where the worldwide status is unchanged.
- **Change in Status** — highlighting progress of a compound through development.
- **Compound Identified** — compounds which were previously identified by a non-specific identifier or a "Pharmaprojects" Number, which now have a research code number or some other way to be specifically identified.
- **Development Continuing** — compounds (previously listed as 'No development reported') for which continuing development has been confirmed.
- **Discontinued Products** — compounds whose development has been discontinued, along with the highest stage of development reached prior to discontinuation and the reason for discontinuation.
- **First Launches** — compounds which have reached the market for the first time, along with the country of first launch. Where the term NAS appears, this means that this is a first launch for a new active substance.
- **First Registrations** — compounds which have been approved for the first time worldwide in any market, giving details of the country of approval.
- **Licences Discontinued** — compounds for which licences have been discontinued.
- **Licensing Opportunities** — compounds being offered for licensing by the manufacturer or academic institution concerned. The country or countries for which they are offered are also given and further details may be found in the full text.
- **Names Granted** — compounds which now have been granted an approved name. They are generally known by a research code only up to this point.
- **New Chemical Structure** — compounds for which a new chemical structure has been identified (highlighted as new), and those where the structure of the lead has changed (highlighted as changed).
- **New Indication** — Compounds which are being actively developed for a new specific disease.
- **New Licensees** — additional licensees identified for a particular compound, with the company and countries of the licence displayed
- **New Patent Applications**— details of compounds or series of compounds new to "Pharmaprojects" which have been identified from European or International (PCT) patent filings.
- **New Product in Pharmaprojects** — all development compounds appearing for the first time in "Pharmaprojects".
- **New Therapeutic Activity** — compounds for which a new therapeutic activity has been discovered.

*(Subscriber access.)

- **No Development Reported** — compounds for which there is no evidence of continuing development in the past 12 months, and for which the companies involved have declined to comment on whether or not development is discontinued.
- **Novel Target reported** — very first record containing a target new to “Pharmaprojects”, with target name and Entrez Gene (Locus Link) ID displayed.
- **Orphan Drug Status Granted** — drugs which have been granted orphan drug status (a period of marketing exclusivity granted to encourage development of drugs for diseases with a low incidences), listing the country or territory where it is granted and the disease for which it has been granted.
- **Pharmacology Identified** — compounds for which the mechanism of action has been identified for the first time, and compounds for which an additional pharmacological activity has been assigned.
- **Registration Submissions** — compounds for which first registration submissions have been made, with the country of filing.
- **Status Reversion** — all backwards status changes, where, for example a product returns to Phase III from pre-registration due to a request for further data and resubmission, or it returns to Phase I from Phase II for reformulation.
- **Suspended Products** — compounds whose development has been temporarily halted, with details of the highest stage reached.
- **Target Identified** — Target is disclosed when it was previously unspecified, with target name and Entrez Gene (Locus Link) ID displayed.
- **Withdrawn** — compounds which have been withdrawn post-launch and the reason for their withdrawal.

Dialog (www.dialog.com), a pioneer of online searching in advance of the internet, is the global leader in providing mission-critical information that drives research in science, engineering, business and intellectual property. The online services provided by Dialog — offered through the Dialog® and DataStar® brands — give users the ability to search through more than 1.5 billion unique records from the world's most authoritative publishers. Sources include in-depth, deep web repositories of scientific, technical and biomedical data, patents and trademarks, and thousands of industry, news and company information sources. Librarians, researchers and information users from corporate, professional and government organizations in more than 100 countries prize Dialog for depth of content, precision searching and the ability to provide complete solutions.

Dialog, LLC, part of the ProQuest (www.proquest.com) family of brands, is headquartered in Morrisville, North Carolina, with offices in Sunnyvale, California, and London.

DIALOG Corporate Headquarters
2250 Perimeter Park Drive
Suite 300
Morrisville, NC 27560
1-800-3 DIALOG

DIALOG Europe, Middle East, Africa
St. Andrews House
18-20 St. Andrew Street
London EC4A 3 AG, UK
+44 (0)20 7832 1729

Contact the Dialog Knowledge Center
Within North America **1 800 3 DIALOG (334 2564)**
Outside North America **00 800 33 DIALOG (33 34 2564)**
Email: Customer@dialog.com